MX2015005841A - Compuestos y composiciones terapeuticos y su uso como moduladores pkm2. - Google Patents
Compuestos y composiciones terapeuticos y su uso como moduladores pkm2.Info
- Publication number
- MX2015005841A MX2015005841A MX2015005841A MX2015005841A MX2015005841A MX 2015005841 A MX2015005841 A MX 2015005841A MX 2015005841 A MX2015005841 A MX 2015005841A MX 2015005841 A MX2015005841 A MX 2015005841A MX 2015005841 A MX2015005841 A MX 2015005841A
- Authority
- MX
- Mexico
- Prior art keywords
- compositions
- therapeutic compounds
- pkm2
- modulators
- pkm2 modulators
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Epidemiology (AREA)
- Enzymes And Modification Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
En la presente se describen composiciones que comprenden compuestos de fórmula general (I) (ver Fórmula) que modulan la piruvato quinasa. También se describen en la presente métodos de uso de los compuestos que modulan piruvato quinasa en el tratamiento de enfermedades.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261724266P | 2012-11-08 | 2012-11-08 | |
PCT/US2013/069193 WO2014074848A1 (en) | 2012-11-08 | 2013-11-08 | Therapeutic compounds and compositions and their use as pkm2 modulators |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2015005841A true MX2015005841A (es) | 2016-01-08 |
Family
ID=49667584
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2015005841A MX2015005841A (es) | 2012-11-08 | 2013-11-08 | Compuestos y composiciones terapeuticos y su uso como moduladores pkm2. |
Country Status (12)
Country | Link |
---|---|
US (1) | US9458132B2 (es) |
EP (1) | EP2917207A1 (es) |
JP (1) | JP6362610B2 (es) |
KR (1) | KR20150080619A (es) |
CN (1) | CN104822672B (es) |
AU (1) | AU2013342203B2 (es) |
CA (1) | CA2890664A1 (es) |
EA (1) | EA032007B1 (es) |
HK (1) | HK1213888A1 (es) |
MX (1) | MX2015005841A (es) |
NZ (1) | NZ707778A (es) |
WO (1) | WO2014074848A1 (es) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK2909181T3 (da) | 2012-10-16 | 2017-11-20 | Tolero Pharmaceuticals Inc | PKM2-modulatorer og fremgangsmåder til anvendelse deraf |
AU2014216178B2 (en) | 2013-02-15 | 2018-06-28 | KALA BIO, Inc. | Therapeutic compounds and uses thereof |
US9688688B2 (en) | 2013-02-20 | 2017-06-27 | Kala Pharmaceuticals, Inc. | Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof |
ES2831625T3 (es) | 2013-02-20 | 2021-06-09 | Kala Pharmaceuticals Inc | Compuestos terapéuticos y sus usos |
JP6426194B2 (ja) | 2013-11-01 | 2018-11-21 | カラ ファーマシューティカルズ インコーポレイテッド | 治療用化合物の結晶形態及びその使用 |
US9890173B2 (en) | 2013-11-01 | 2018-02-13 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
CN104817490B (zh) * | 2015-05-13 | 2017-10-13 | 北京大学 | 氨基二硫代甲酸酯类化合物及其制备方法与应用 |
WO2017095751A1 (en) | 2015-12-02 | 2017-06-08 | Partikula Llc | Compositions and methods for modulating cancer cell metabolism |
CA2968836A1 (en) | 2016-06-13 | 2017-12-13 | Gilead Sciences, Inc. | Fxr (nr1h4) modulating compounds |
BR112019004463A2 (pt) | 2016-09-08 | 2019-05-28 | Kala Pharmaceuticals Inc | formas cristalinas de compostos terapêuticos, seus processos de obtenção e seus métodos de uso |
EP3509422A4 (en) | 2016-09-08 | 2020-05-20 | Kala Pharmaceuticals, Inc. | CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF |
US10392399B2 (en) | 2016-09-08 | 2019-08-27 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
RS60209B1 (sr) * | 2017-03-20 | 2020-06-30 | Forma Therapeutics Inc | Kompozicije pirolopirola kao aktivatori piruvat kinaze (pkr) |
PT3668513T (pt) | 2017-08-15 | 2022-01-21 | Agios Pharmaceuticals Inc | Ativadores da piruvato quinase para uso no tratamento de distúrbios do sangue |
WO2019075367A1 (en) | 2017-10-13 | 2019-04-18 | Tolero Pharmaceuticals, Inc. | PKM2 ACTIVATORS IN COMBINATION WITH OXYGEN REACTIVE SPECIES FOR THE TREATMENT OF CANCER |
US20220031671A1 (en) | 2018-09-19 | 2022-02-03 | Forma Therapeutics, Inc. | Treating sickle cell disease with a pyruvate kinase r activating compound |
WO2020061255A1 (en) | 2018-09-19 | 2020-03-26 | Forma Therapeutics, Inc. | Activating pyruvate kinase r |
WO2020198077A1 (en) | 2019-03-22 | 2020-10-01 | Sumitomo Dainippon Pharma Oncology, Inc. | Compositions comprising pkm2 modulators and methods of treatment using the same |
WO2022170200A1 (en) | 2021-02-08 | 2022-08-11 | Global Blood Therapeutics, Inc. | 1-(2-sulfonyl-2,6-dihydropyrrolo[3,4-c]pyrazol-5(4h)-yl]-ethanone derivatives as pyruvate kinase (pkr) and pkm2 activators for the treatment of sickle cell disease |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3545461B2 (ja) | 1993-09-10 | 2004-07-21 | エーザイ株式会社 | 二環式ヘテロ環含有スルホンアミド誘導体 |
US6214879B1 (en) | 1998-03-24 | 2001-04-10 | Virginia Commonwealth University | Allosteric inhibitors of pyruvate kinase |
KR100692232B1 (ko) | 1999-09-04 | 2007-03-09 | 아스트라제네카 아베 | 피루베이트 탈수소효소 활성을 증가시키는 치환된 n-페닐2-히드록시-2-메틸-3,3,3-트리플루오로프로판아미드 유도체 |
WO2006033628A1 (en) | 2004-09-24 | 2006-03-30 | Astrazeneca Ab | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof |
EP2344453B1 (en) * | 2008-10-09 | 2016-12-28 | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services | Activators of human pyruvate kinase |
MX346801B (es) | 2009-03-13 | 2017-03-31 | Agios Pharmaceuticals Inc | Métodos y composiciones para trastornos relacionados con la proliferación celular. |
CN102448951B (zh) * | 2009-04-06 | 2017-05-10 | 安吉奥斯医药品有限公司 | 丙酮酸激酶m2调节剂、治疗组合物和相关使用方法 |
AU2010238732B2 (en) | 2009-04-22 | 2015-06-11 | Janssen Pharmaceutica Nv | Azetidinyl diamides as monoacylglycerol lipase inhibitors |
KR101850813B1 (ko) * | 2009-06-29 | 2018-04-20 | 아지오스 파마슈티컬스 아이엔씨. | 치료용 화합물 및 조성물 |
EP2448581B1 (en) * | 2009-06-29 | 2016-12-07 | Agios Pharmaceuticals, Inc. | Therapeutic compositions and related methods of use |
AU2011245441B2 (en) * | 2010-04-29 | 2014-12-18 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Activators of human pyruvate kinase |
DE102010048800A1 (de) | 2010-10-20 | 2012-05-10 | Merck Patent Gmbh | Chinoxalinderivate |
EP2651898B1 (en) * | 2010-12-17 | 2015-12-09 | Agios Pharmaceuticals, Inc. | Novel n-(4-(azetidine-1-carbonyl)phenyl)-(hetero-)arylsulfonamide derivatives as pyruvate kinase m2 (pmk2) modulators |
TWI549947B (zh) * | 2010-12-29 | 2016-09-21 | 阿吉歐斯製藥公司 | 治療化合物及組成物 |
ME03074B (me) * | 2011-05-03 | 2019-01-20 | Agios Pharmaceuticals Inc | Akтivatori piruvat kinaze za upotrebu u terapiji |
US9388164B2 (en) * | 2011-05-03 | 2016-07-12 | Agios Pharmaceuticals, Inc | Methods of using pyruvate kinase activators |
-
2013
- 2013-11-08 CA CA2890664A patent/CA2890664A1/en not_active Abandoned
- 2013-11-08 EP EP13795929.2A patent/EP2917207A1/en not_active Withdrawn
- 2013-11-08 JP JP2015541933A patent/JP6362610B2/ja not_active Expired - Fee Related
- 2013-11-08 AU AU2013342203A patent/AU2013342203B2/en not_active Ceased
- 2013-11-08 NZ NZ707778A patent/NZ707778A/en not_active IP Right Cessation
- 2013-11-08 US US14/441,746 patent/US9458132B2/en not_active Expired - Fee Related
- 2013-11-08 EA EA201590881A patent/EA032007B1/ru not_active IP Right Cessation
- 2013-11-08 MX MX2015005841A patent/MX2015005841A/es unknown
- 2013-11-08 WO PCT/US2013/069193 patent/WO2014074848A1/en active Application Filing
- 2013-11-08 CN CN201380063407.2A patent/CN104822672B/zh not_active Expired - Fee Related
- 2013-11-08 KR KR1020157014747A patent/KR20150080619A/ko not_active Application Discontinuation
-
2016
- 2016-02-18 HK HK16101847.5A patent/HK1213888A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
EP2917207A1 (en) | 2015-09-16 |
JP6362610B2 (ja) | 2018-07-25 |
CA2890664A1 (en) | 2014-05-15 |
EA201590881A1 (ru) | 2015-08-31 |
CN104822672B (zh) | 2018-08-28 |
US9458132B2 (en) | 2016-10-04 |
AU2013342203A1 (en) | 2015-05-21 |
EA032007B1 (ru) | 2019-03-29 |
JP2016501189A (ja) | 2016-01-18 |
US20150307473A1 (en) | 2015-10-29 |
KR20150080619A (ko) | 2015-07-09 |
CN104822672A (zh) | 2015-08-05 |
HK1213888A1 (zh) | 2016-07-15 |
NZ707778A (en) | 2019-03-29 |
AU2013342203B2 (en) | 2017-11-23 |
WO2014074848A1 (en) | 2014-05-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NZ707778A (en) | Therapeutic compounds and compositions and their use as pkm2 modulators | |
PH12015502161A1 (en) | Therapeutic compounds and compositions | |
MX342274B (es) | Actividades de la piruvato quinasa m2 (pkm2). | |
PH12016500105A1 (en) | Sulfonamides as modulators of sodium channels | |
IN2015DN01156A (es) | ||
MX2020010535A (es) | Inhibidor de ezh2 para usarse en el tratamiento de sarcoma epiteloide. | |
MX2015009592A (es) | Quinolina y quinazolina amidas como moduladores de canales de sodio. | |
MY191825A (en) | Therapeutic compounds and compositions | |
EP4230264A3 (en) | Prodrugs of fumarates and their use in treating various deseases | |
EA024842B9 (ru) | Соединения в качестве модуляторов протеинкиназы pi3k | |
ECSP14017269A (es) | Compuestos para tratar la atrofia muscular espinal | |
NZ708382A (en) | Cycloalkyl bis-thiadiazole inhibitors of glutaminase and their use as therapeutic agents | |
EA201590165A1 (ru) | Сдерживающие злоупотребление фармацевтические композиции для контролируемого высвобождения | |
NZ700928A (en) | Dna-pk inhibitors | |
MX346147B (es) | Compuestos de 3-aril-5-substituido-isoquinolin-1-ona y su uso terapeutico. | |
MX356755B (es) | Compuestos de tipo fumagilol y metodos para su elaboración y uso. | |
PH12014502032A1 (en) | Treatment of brain cancer | |
PH12015501038A1 (en) | Inhibitors of iap | |
GB201213484D0 (en) | Pharmaceutical compositions comprising 15-OHEPA and methods of using the same | |
MX365192B (es) | Derivados de bendamustina y compuestos relacionados, y uso medico de los mismos para la terapia de cancer. | |
CY1118255T1 (el) | Υποκατεστημενα 6-αμινο-νικοτιναμιδια τα οποια φερουν μια ομαδα που περιεχει οη ως διαμορφωτες των kcnq2/3 | |
NZ750581A (en) | Compositions and methods for treating neurodegenerative diseases and cardiomyopathy | |
GB2519004A (en) | Quinone compounds and their uses for the treatment of cancer |